Skip to main content

HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase.

Publication ,  Journal Article
Ginzel, JD; Acharya, CR; Lubkov, V; Mori, H; Boone, PG; Rochelle, LK; Roberts, WL; Everitt, JI; Hartman, ZC; Crosby, EJ; Barak, LS; Caron, MG ...
Published in: Mol Cancer Res
October 2021

HER2-positive breast cancers are among the most heterogeneous breast cancer subtypes. The early amplification of HER2 and its known oncogenic isoforms provide a plausible mechanism in which distinct programs of tumor heterogeneity could be traced to the initial oncogenic event. Here a Cancer rainbow mouse simultaneously expressing fluorescently barcoded wildtype (WTHER2), exon-16 null (d16HER2), and N-terminally truncated (p95HER2) HER2 isoforms is used to trace tumorigenesis from initiation to invasion. Tumorigenesis was visualized using whole-gland fluorescent lineage tracing and single-cell molecular pathology. We demonstrate that within weeks of expression, morphologic aberrations were already present and unique to each HER2 isoform. Although WTHER2 cells were abundant throughout the mammary ducts, detectable lesions were exceptionally rare. In contrast, d16HER2 and p95HER2 induced rapid tumor development. d16HER2 incited homogenous and proliferative luminal-like lesions which infrequently progressed to invasive phenotypes whereas p95HER2 lesions were heterogenous and invasive at the smallest detectable stage. Distinct cancer trajectories were observed for d16HER2 and p95HER2 tumors as evidenced by oncogene-dependent changes in epithelial specification and the tumor microenvironment. These data provide direct experimental evidence that intratumor heterogeneity programs begin very early and well in advance of screen or clinically detectable breast cancer. IMPLICATIONS: Although all HER2 breast cancers are treated equally, we show a mechanism by which clinically undetected HER2 isoforms program heterogenous cancer phenotypes through biased epithelial specification and adaptations within the tumor microenvironment.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Mol Cancer Res

DOI

EISSN

1557-3125

Publication Date

October 2021

Volume

19

Issue

10

Start / End Page

1699 / 1711

Location

United States

Related Subject Headings

  • Tumor Microenvironment
  • Receptor, erbB-2
  • Receptor, ErbB-2
  • Protein Isoforms
  • Oncology & Carcinogenesis
  • Mice, Knockout
  • Mice
  • Gene Expression Regulation, Neoplastic
  • Female
  • Developmental Biology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ginzel, J. D., Acharya, C. R., Lubkov, V., Mori, H., Boone, P. G., Rochelle, L. K., … Snyder, J. C. (2021). HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase. Mol Cancer Res, 19(10), 1699–1711. https://doi.org/10.1158/1541-7786.MCR-21-0215
Ginzel, Joshua D., Chaitanya R. Acharya, Veronica Lubkov, Hidetoshi Mori, Peter G. Boone, Lauren K. Rochelle, Wendy L. Roberts, et al. “HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase.Mol Cancer Res 19, no. 10 (October 2021): 1699–1711. https://doi.org/10.1158/1541-7786.MCR-21-0215.
Ginzel JD, Acharya CR, Lubkov V, Mori H, Boone PG, Rochelle LK, et al. HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase. Mol Cancer Res. 2021 Oct;19(10):1699–711.
Ginzel, Joshua D., et al. “HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase.Mol Cancer Res, vol. 19, no. 10, Oct. 2021, pp. 1699–711. Pubmed, doi:10.1158/1541-7786.MCR-21-0215.
Ginzel JD, Acharya CR, Lubkov V, Mori H, Boone PG, Rochelle LK, Roberts WL, Everitt JI, Hartman ZC, Crosby EJ, Barak LS, Caron MG, Chen JQ, Hubbard NE, Cardiff RD, Borowsky AD, Lyerly HK, Snyder JC. HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase. Mol Cancer Res. 2021 Oct;19(10):1699–1711.

Published In

Mol Cancer Res

DOI

EISSN

1557-3125

Publication Date

October 2021

Volume

19

Issue

10

Start / End Page

1699 / 1711

Location

United States

Related Subject Headings

  • Tumor Microenvironment
  • Receptor, erbB-2
  • Receptor, ErbB-2
  • Protein Isoforms
  • Oncology & Carcinogenesis
  • Mice, Knockout
  • Mice
  • Gene Expression Regulation, Neoplastic
  • Female
  • Developmental Biology